Contact UsCareersNewsScienceContact Us
Deconstructing The Potential Threat Of AMR Via Online LearningHomeOur Community EffortsCSR InitiativesAntimicrobial Resistance

A recent study represents how an estimated 4.95 million people who died in 2019 suffered from at least one drug-resistant infection and AMR directly caused 1.27 million of those deaths. (1)  Novel resistance mechanisms are evolving and spreading rapidly, threatening the healthcare system’s ability to treat common infectious diseases. (2) When we take a step back and assess the current pool, it is evident that each one of us is at risk from AMR which is a major threat to global health, food security, and development in today’s reality. (3)

Pfizer is spearheading the movement against AMR in India
 

We at Pfizer, are aware that nurses play a critical role in ensuring that good antimicrobial stewardship and infection control measures are practiced in hospitals across the nation. Our goal is to raise effective awareness of AMR and the major threat it poses to modern healthcare. In our journey to achieve this goal, we have supported the launch of a first-of-its-kind multi-lingual learning platform, OPEN—the Online Platform for Education among Nurses!

The introduction of the OPEN-AMR program further strengthens Pfizer’s Project Parivartan, a program focused on addressing the current challenges in Infection Prevention and Control (IPC). The OPEN-AMR program aligns with Project Parivartan’s six-pronged goal which focuses on key aspects such as: 

  1. Strengthening India’s leadership on AMR
  2. Optimizing the use of antimicrobial agents in health
  3. Promoting investments for AMR activities, research, and innovations
  4. Improving awareness and understanding of AMR through effective communication, education, and training
  5. Strengthening knowledge and evidence through surveillance
  6. Reducing the incidence of infection through effective infection prevention and control

At present Project Parivartan is helping transform 11 hospitals across 7 states such as Maharashtra, Uttar Pradesh, and Tamil Nadu amongst others. The aim of the program is to demonstrate a measurable improvement in key Infection Prevention Control (IPC) parameters in these mid-sized hospitals.

How will the platform help? 

OPEN-AMR is a web-based platform that can be accessed by nurses across the country in seven different languages: English, Hindi, Malayalam, Tamil, Telugu, Kannada, and Marathi. The courses on the platform have been curated by experts and are available free of cost to nurses and hospitals. 

Commenting on the value of this program, Sharad Goswami, Senior Director-Corporate Affairs, Pfizer Limited, said, “The fight against antimicrobial resistance has been a global priority for Pfizer for years now. Nurses play a critical role in ensuring good antimicrobial stewardship and infection control measures are practised in the healthcare ecosystem. We are pleased to partner with Americares India Foundation and Medivarsity to make OPEN and AMR courses accessible to every nurse in India."
 
Amplifying our outreach on AMR further
 
Pfizer in association with Americares India Foundation and Integrated Health & Wellbeing Council hosted India’s first “Antimicrobial Resistance Summit 2022”. The Summit brought together key leaders and experts from across government, healthcare, medical & research institutions, and scientists, who explored and highlighted the threats and risks posed by AMR in the Indian and global context, and the way forward to mitigate the rise of AMR. OPEN-AMR was unveiled at this prestigious event.

The summit was attended by industry veterans such as Ms KK Shailaja, Teacher and Hon’ble Former Minister of Health and Family Welfare, Kerala, Mr Shripad Desai, Managing Director, Americares India Foundation and Mr Sharad Goswami, Senior Director-Corporate Affairs, Pfizer Limited among others.
 
The discussion explored challenges in infection prevention from a health and economic perspective, as well as bridging the antibiotic resistance gap.
 
With innovation at the core of our efforts, Pfizer will continue to spearhead global health awareness initiatives and projects.
 

Reference:

(1)    Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E, Johnson SC. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022 Feb 12;399(10325):629-55.
(2)    Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and therapeutics. 2015 Apr;40(4):277.
(3)    Prestinaci F, Pezzotti P, Pantosti A. Antimicrobial resistance: a global multifaceted phenomenon. Pathogens and global health. 2015 Oct 3;109(7):309-18.

RELATED ARTICLES


INDovation: Healthcare innovations made in India

Project Aastha: End-to-end patient support

Fostering innovation in healthcare

Putting the ‘care’ in Cancer Care

Raising ummeed, one case at a time

Transforming lives, one village at a time

Going back to basics with hygiene and sanitation

Providing relief in times of need

Creating social impact through volunteering
About UsOur ScienceOur Community EffortsYour Health Career-Seekers News & MediaHealthcare ProfessionalsContact UsTerms And ConditionsPrivacy PolicyAdverse Event ReportingCopyright © 2002- 2022 Pfizer Inc. All rights reserved. This information—including product information—is intended only for residents of  India and strictly only for informational, educational, academic and/or research purposes and is not intended to substitute for professional medical advice, diagnosis or treatment. While due care and caution has been taken to ensure that the content here is free from mistakes or omissions, Pfizer makes no claims, promises or guarantees about the accuracy, completeness or adequacy of the information here. You may report an adverse event related to Pfizer products by emailing us at IND.AEReporting@pfizer.com or via Fax at: 000800100-5961 / +91-22 3919-771.